The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Current and future pharmacological therapies for NAFLD/NASH
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. The first approach is targeting hepatic fat accumulation. Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. A second target is oxidative stress, inflammation, and apoptosis. This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. Antifibrotic agents are a cysteine-cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Lippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., et al. (2009) · JAMA · doi:10.1001/jama.2008.864 · Cited by 2,122
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Decoding cell death signals in liver inflammation
Brenner, C., Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.033 · Cited by 1,022
Xiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 1×
“A RCT in a small group of obese T2DM patients with FGF-21 found significant improvement in lipid profiles as well as weight loss, reduced insulin levels, and raised adiponectin [84].”
BackgroundRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Imajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
Self-citationUrsodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727 · cited 1×
“According to a large, multicenter RCT, standard dose of UDCA has no effects on liver histology in NASH [23], although some studies suggest that high dosage of this agent may show a favorable effect.”
BackgroundAithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Rivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693 · cited 1×
“Inhibition of the TLR4 signaling pathway may provide an effective therapy in the prevention of inflammatory hepatic injury and hepatic fibrosis in NASH patients [75].”
BackgroundFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638
Goldberg, D., Ditah, I. C., Saeian, K., Lalehzari, M., Aronsohn, A., Gorospe, E. C., & Charlton, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.003 · Cited by 604
JSG-NAFLD, Eguchi, Y., Hyogo, H., Ono, M., Mizuta, T., Ono, N., Fujimoto, K., Chayama, K., & Saibara, T. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0533-z · Cited by 551
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
The regulation of inflammation by galectin‐3
Henderson, N. C., & Sethi, T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00794.x · Cited by 522
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309265 · Cited by 480
Yokohama, S., Yoneda, M., Haneda, M., Okamoto, S., Okada, M., Aso, K., Hasegawa, T., Tokusashi, Y., Miyokawa, N., & Nakamura, K. (2004) · Hepatology · doi:10.1002/hep.20420 · Cited by 458
Self-citationSingh, S., Singh, P. P., Singh, A. G., Murad, M. H., & Sanchez, W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.005 · Cited by 452
Reilly, S. M., Chiang, S.-H., Decker, S. J., Chang, L., Uhm, M., Larsen, M. J., Rubin, J. R., Mowers, J., White, N. M., Hochberg, I., et al. (2013) · Nature Medicine · doi:10.1038/nm.3082 · Cited by 433
Yoneda, M., Yoneda, M., Mawatari, H., Fujita, K., Endo, H., Iida, H., Nozaki, Y., Yonemitsu, K., Higurashi, T., Takahashi, H., et al. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.019 · Cited by 428
Self-citationStaels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“Elafibranor (GFT505) Elafibranor is an unlicensed dual agonist of PPARa/d receptors, and has been shown to improve steatosis, inflammation, and fibrosis in mouse models of NAFLD [30].”
BackgroundHasegawa, T., Yoneda, M., Nakamura, K., Makino, I., & Terano, A. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01083.x · Cited by 408
Self-citationManagement of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., Kanemasa, K., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-2 · Cited by 383
Self-citationEffects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials
Schurks, M., Glynn, R. J., Rist, P. M., Tzourio, C., & Kurth, T. (2010) · BMJ · doi:10.1136/bmj.c5702 · Cited by 380
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Loomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J., Kono, Y., Bhatt, A., et al. (2015) · Hepatology · doi:10.1002/hep.27647 · Cited by 344
Malonyl-CoA: the regulator of fatty acid synthesis and oxidation
Foster, D. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63967 · Cited by 336
(2012) · Hepatogastroenterology · doi:10.5754/hge12420 · Cited by 332
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1050-7 · Cited by 327
Self-citationSberna, A. L., Bouillet, B., Rouland, A., Brindisi, M. C., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13565 · Cited by 322
Koehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Scorletti, E., Bhatia, L., McCormick, K. G., Clough, G. F., Nash, K., Hodson, L., Moyses, H. E., Calder, P. C., Byrne, C. D., Sheron, N., et al. (2014) · Hepatology · doi:10.1002/hep.27289 · Cited by 310
Sanyal, A. J., Abdelmalek, M. F., Suzuki, A., Cummings, O. W., & Chojkier, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.046 · Cited by 309
Barreyro, F. J., Holod, S., Finocchietto, P. V., Camino, A. M., Aquino, J. B., Avagnina, A., Carreras, M. C., Poderoso, J. J., & Gores, G. J. (2015) · Liver International · doi:10.1111/liv.12570 · Cited by 294
Involvement of free radicals and oxidative stress in NAFLD/NASH
Sumida, Y., Niki, E., Naito, Y., & Yoshikawa, T. (2013) · Free Radical Research · doi:10.3109/10715762.2013.837577 · Cited by 280 · cited 1×
“Vitamin E Oxidative stress has been implicated to have an important role in the progression of NASH [10, 11].”
BackgroundSelf-citationIto, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Safadi, R., Konikoff, F. M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., Safadi, R., Konikoff, F. M., Hershkovitz, A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.038 · Cited by 274
Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151511 · Cited by 228
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
Sumida, Y., Nakashima, T., Yoh, T., Furutani, M., Hirohama, A., Kakisaka, Y., Nakajima, Y., Ishikawa, H., Mitsuyoshi, H., Okanoue, T., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00331-8 · Cited by 215
Self-citationVascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Weston, C. J., Shepherd, E. L., Claridge, L. C., Rantakari, P., Curbishley, S. M., Tomlinson, J. W., Hubscher, S. G., Reynolds, G. M., Aalto, K., Anstee, Q. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73722 · Cited by 214
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Doycheva, I., Cui, J., Nguyen, P., Costa, E. A., Hooker, J., Hofflich, H., Bettencourt, R., Brouha, S., Sirlin, C. B., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13405 · Cited by 210
Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208
Hoofnagle, J. H., Van Natta, M. L., Kleiner, D. E., Clark, J. M., Kowdley, K. V., Loomba, R., Neuschwander‐Tetri, B. A., Sanyal, A. J., Tonascia, J., & the Non‐alcoholic Steatohepatitis Clinical Research Network (NASH CRN) (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12352 · Cited by 201
Sato, K., Gosho, M., Yamamoto, T., Kobayashi, Y., Ishii, N., Ohashi, T., Nakade, Y., Ito, K., Fukuzawa, Y., & Yoneda, M. (2015) · Nutrition · doi:10.1016/j.nut.2014.11.018 · Cited by 201
Self-citationWatanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 200
Self-citationEfficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
Park, H., Shima, T., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., Itoh, Y., Yoshikawa, T., Fukui, M., Hasegawa, G., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-010-0291-8 · Cited by 195
Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 191
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L., & Vancica, L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.942 · Cited by 177
Harrison, S. A., Marri, S. R., Chalasani, N., Kohli, R., Aronstein, W., Thompson, G. A., Irish, W., Miles, M. V., Xanthakos, S. A., Lawitz, E., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13816 · Cited by 176
Ursodeoxycholic Acid Protects Hepatocytes against Oxidative Injury via Induction of Antioxidants
Mitsuyoshi, H., Nakashima, T., Sumida, Y., Yoh, T., Nakajima, Y., Ishikawa, H., Inaba, K., Sakamoto, Y., Okanoue, T., & Kashima, K. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1403 · Cited by 169
Self-citationJapan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD), Nakahara, T., Hyogo, H., Yoneda, M., Sumida, Y., Eguchi, Y., Fujii, H., Ono, M., Kawaguchi, T., Imajo, K., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-013-0911-1 · Cited by 163
Self-citationCostabel, U., Albera, C., LANCASTER, L. H., Lin, C.-Y., Hormel, P., Hulter, H. N., & Noble, P. W. (2017) · Respiration · doi:10.1159/000479976 · Cited by 161
Honda, Y., Kessoku, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., Takizawa, T., Saito, S., Nagashima, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42477 · Cited by 148
Self-citationMoon, H.-J., Finney, J., Ronnebaum, T. A., & Mure, M. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.07.003 · Cited by 147
Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.912983 · Cited by 146
(2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.001 · Cited by 144
Efficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study
Yoneda, M., Fujita, K., Nozaki, Y., Endo, H., Takahashi, H., Hosono, K., Suzuki, K., Mawatari, H., Kirikoshi, H., Inamori, M., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00644.x · Cited by 142
Self-citationEffect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 133
Honda, Y., Kessoku, T., Sumida, Y., Kobayashi, T., Kato, T., Ogawa, Y., Tomeno, W., Imajo, K., Fujita, K., Yoneda, M., et al. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0652-3 · Cited by 129
Self-citationEffects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis
Du, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.569 · Cited by 128
Nakamura, J., Kamiya, H., Haneda, M., Inagaki, N., Tanizawa, Y., Araki, E., Ueki, K., & Nakayama, T. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12645 · Cited by 121
Vatner, D. F., Weismann, D., Beddow, S. A., Kumashiro, N., Erion, D. M., Liao, X.-H., Grover, G. J., Webb, P., Phillips, K. J., Weiss, R. E., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00573.2012 · Cited by 119
Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients
Hamaguchi, E., Takamura, T., Sakurai, M., Mizukoshi, E., Zen, Y., Takeshita, Y., Kurita, S., Arai, K., Yamashita, T., Sasaki, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0148 · Cited by 112
Akuta, N., Watanabe, C., Kawamura, Y., Arase, Y., Saitoh, S., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1019 · Cited by 112
Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
Itoh, N., Nakayama, Y., & Konishi, M. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00030 · Cited by 106
Nakamura, J., Kamiya, H., Haneda, M., Inagaki, N., Tanizawa, Y., Araki, E., Ueki, K., & Nakayama, T. (2017) · Diabetology International · doi:10.1007/s13340-017-0313-3 · Cited by 106
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Ruzehaji, N., Frantz, C., Ponsoye, M., Avouac, J., Pezet, S., Guilbert, T., Luccarini, J., Broqua, P., Junien, J., & Allanore, Y. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208029 · Cited by 103
Roulot, D. M., Roudot‐Thoraval, F., Nkontchou, G., Kouacou, N., Costes, J., Elourimi, G., Clésiau, H. L., Ziol, M., & Beaugrand, M. (2017) · Liver International · doi:10.1111/liv.13481 · Cited by 97
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12834 · Cited by 94
Self-citationOza, N., Eguchi, Y., Mizuta, T., Ishibashi, E., Kitajima, Y., Horie, H., Ushirogawa, M., Tsuzura, T., Nakashita, S., Takahashi, K., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0115-x · Cited by 93
Ezetimibe for the treatment of non‐alcoholic fatty liver disease: A meta‐analysis
Nakade, Y., Murotani, K., Inoue, T., Kobayashi, Y., Yamamoto, T., Ishii, N., Ohashi, T., Ito, K., Fukuzawa, Y., & Yoneda, M. (2017) · Hepatology Research · doi:10.1111/hepr.12887 · Cited by 83
Self-citationDePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C. S., & Dunn, F. L. (2014) · Diabetes Care · doi:10.2337/dc13-2480 · Cited by 81
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
Avouac, J., Konstantinova, I., Guignabert, C., Pezet, S., Sadoine, J., Guilbert, T., Cauvet, A., Tu, L., Luccarini, J., Junien, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210821 · Cited by 80
Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76
Yaʼacov, A. B., Mizrahi, M., Shabat, Y., Lalazar, G., Adar, T., Wong, V., Muller, B. D., Rawlin, G., & Ilan (2012) · Journal of Inflammation Research · doi:10.2147/jir.s35227 · Cited by 75
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 71
Self-citationBezafibrate for tamoxifeninduced non-alcoholic steatohepatitis
Saibara, T., Onishi, S., Ogawa, Y., Yoshida, S., & Enzan, H. (1999) · The Lancet · doi:10.1016/s0140-6736(05)75907-9 · Cited by 70
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
Komiya, C., Tanaka, M., Tsuchiya, K., Shimazu, N., Mori, K., Furuke, S., Miyachi, Y., Shiba, K., Yamaguchi, S., Ikeda, K., et al. (2017) · Scientific Reports · doi:10.1038/srep44754 · Cited by 69
Gómez, E. V., Garcia, A. Y., Pérez, Y. M., Bertot, L. C., Gonzalez, A. T., Gra‐Oramas, B., Gonzalez‐Fabian, L., Villa-Jiménez, O. M., Friedman, S. L., Diago, M., et al. (2016) · Hepatology · doi:10.1002/hep.28484 · Cited by 66
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Yamaguchi, K., Moriguchi, M., et al. (2014) · Hepatology Research · doi:10.1111/hepr.12456 · Cited by 62
Self-citationA randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
McPherson, S., Wilkinson, N., TINIAKOS, D. G., Wilkinson, J. S., Burt, A. D., McColl, E., Stocken, D. D., Steen, N. D., Barnes, J. A., Goudie, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175717 · Cited by 60
Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2016) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Self-citationCCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study
Prospero, N. A. D., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N. M., Xi, L., & Rothenberg, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12309 · Cited by 53
Shetty, S., Kumar, S., Mathur, R. P., Sharma, K. H., & Jaiswal, A. D. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.02.007 · Cited by 48
Takeda, A., Irahara, A., Nakano, A., Takata, E., Koketsu, Y., Kimata, K., Senda, E., Yamada, H., Ichikawa, K., Fujimori, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8754-16 · Cited by 37
Self-citationLong-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.
Sumida, Y., Naito, Y., Tanaka, S., Sakai, K., Inada, Y., Taketani, H., Kanemasa, K., Yasui, K., Itoh, Y., Okanoue, T., et al. (2013) · PubMed · doi:10.5754/hge11421 · Cited by 30
Self-citationOkajima, A., Sumida, Y., Taketani, H., Hara, T., Seko, Y., Ishiba, H., Nishimura, T., Umemura, A., Nishikawa, T., Yamaguchi, K., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12793 · Cited by 27
Self-citationShima, T., Uto, H., Ueki, K., Takamura, T., Kohgo, Y., Kawata, S., Yasui, K., Park, H., Nakamura, N., Nakatou, T., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0653-5 · Cited by 26
Gilat, T., Leikin-Frenkel, A. I., Goldiner, I., Laufer, H., Halpern, Z., & Konikoff, F. M. (2001) · Lipids · doi:10.1007/s11745-001-0824-3 · Cited by 26
Assessment of transient elastography in Japanese patients with non‐alcoholic fatty liver disease
Seki, K., Shima, T., Oya, H., Mitsumoto, Y., Mizuno, M., & Okanoue, T. (2016) · Hepatology Research · doi:10.1111/hepr.12829 · Cited by 21
Semaglutide, lipid-lowering drugs, and NAFLD
Katsiki, N., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30109-2 · Cited by 19
Leeming, D. J., Grove, J. I., Kaye, P., Hoad, C. L., Francis, S., Nielsen, M. J., Karsdal, M. A., Guha, I. N., & Aithal, G. P. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30582-2 · Cited by 19
Cited by
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N. P., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 439
Metadata
- Authors
- Sumida, Y., & Yoneda, M.
- Venue
- Journal of Gastroenterology
- Published
- 2017-12-16
- Volume
- 53
- Issue
- 3
- Pages
- 362-376
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2772777089
- Cited by
- 667
- References
- 112
- FWCI
- 39.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.